[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563566":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":71,"collaborators":26,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":26,"eligibilityCriteria":78,"healthyVolunteers":75,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":26,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":58,"whyStopped":26,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"University of Aarhus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active group","ACTIVE_COMPARATOR","Active drug",[13],"Drug: Active drug for acute migraine treatment",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Inactive placebo",[19],"Drug: Placebo Oral Tablet",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Active drug for acute migraine treatment","Standard dose of Sumatriptan 100 mg, which is used as an acute treatment for episodic migraine",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo Oral Tablet","Inactive placebo pill (100 mg) looking like the active drug",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Sigrid Juhl Lunde, MSc, PhD","CONTACT","4587165956","lunde@psy.au.dk",[38,56],{"facility":39,"status":40,"city":41,"state":26,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Dept. of Psychology and Behavioural Sciences","NOT_YET_RECRUITING","Aarhus C","8000","Denmark","DK",{"type":46,"coordinates":47},"Point",[48,49],10.21231,56.16558,{"lat":49,"lon":48},[52],{"name":53,"role":34,"phone":54,"phoneExt":26,"email":55},"Lene Vase","004530614476","lenevase@psy.au.dk",{"facility":57,"status":58,"city":59,"state":26,"zip":60,"country":43,"countryCode":44,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Department of Neurology, Aarhus University Hospital","RECRUITING","Aarhus N","8200",{"type":46,"coordinates":62},[63,64],10.17317,56.20367,{"lat":64,"lon":63},[67],{"name":68,"role":34,"phone":69,"phoneExt":26,"email":70},"Sonja Antic","+457845 0000","Sonant@rm.dk",{"type":72,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100563566","trial-designs-for-evaluating-migraine-treatment-100563566",false,"NCT06617832","Trial Designs for Evaluating Migraine Treatment","Inclusion Criteria:\n\n1. Adults (18-65 years)\n2. ≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria\n3. Known episodic migraine (≥ 1 and \\< 15 headache days with features of migraine on at least 2-8 days per month for \\> 3 months) with and without aura and diagnosed before age 50\n4. Previous or active use of triptans as acute treatment for migraine\n5. Ability to speak and read Danish\n\nExclusion Criteria:\n\n1. Chronic migraine or history of chronic migraine in the last 12 months\n2. Other concomitant primary headache types except for infrequent tension-type headache\n3. Secondary headache disorders including medication overuse headache\n4. Severe psychiatric, vascular or liver diseases\n5. Opioid or barbiturate use in the month preceding screening\n6. Current use of preventive migraine treatment (i.e., onabotulinum toxin A, and\u002For Calcitonin gene-related peptide (CGRP) monoclonal antibodies) (however, stable medical treatment with other migraine prophylactic agents is permitted, e.g. antidepressant, calcium channel blockers, beta blockers and antiepileptic drugs, 4 weeks prior to inclusion until the completion of participation in the study)\n7. Contraindications or inability to tolerate triptans\n8. Current substance use disorder\n9. Implanted metallic or electronic device in the head\n10. Cardiac pacemaker or implanted or wearable defibrillator\n11. Use of illegal psychotropic drugs less than a week before participation in the study; regarding cannabis: less than four weeks before participation in the study\n12. Current pregnancy or planned pregnancy (confirmed by pregnancy test and by use of safe contraception as defined by the Danish Medicines Agency) and lactation","ALL","18 Years","65 Years",{"count":83,"type":84},128,"ESTIMATED","INTERVENTIONAL",[87],"NA","The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, advanced balanced placebo design, patients with episodic migraine will receive six treatment conditions in a randomized order.",[90,91,92],"Migraine With Aura","Migraine Without Aura","Headache, Migraine",[94,95,96,97,98,99],"Headache","Episodic migraine","Randomized controlled trial","Balanced placebo design","Treatment effects","Adverse events","2026-04-08",{"date":102,"type":103},"2026-04-13","ACTUAL",{"date":105,"type":103},"2024-11-13",{"date":107,"type":84},"2028-09",{"name":5,"class":6},2]